Having thousands of lawsuits alleging drug dangers all in one court can make them easier to manage and potentially defend or settle. But a U.S. District Court judge has thrown Merck a curve in its Fosamax litigation, ordering hundreds of lawsuits returned to the courts from whence they came.
The jury in the latest Fosamax trial has spoken, and it spoke for Merck. In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's broken leg wasn't caused by the bone drug Fosamax. It was the first jury verdict among the more than 3,000 lawsuits claiming Fosamax caused serious femur fractures.
A plaintiff's lawyer in the latest lawsuit claims Merck was warned about the potential for spontaneous fractures 5 years before Fosamax made its debut.
It's Fosamax trial time again. Amid litigation over the bone drug's risks of jawbone injury, Merck is in court to fight claims that Fosamax caused patients' femur fractures. Once again, the drugmaker faces charges that it ignored the drug's safety risks, leaving patients in the dark.
You win some and you lose some and this time, Merck ($MRK) lost to the tune of $285,000 when a jury said it was not up front about the risks of osteoporosis drug Fosamax.
The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007...
Another bellwether Fosamax case is wrapped up, with another victory for Merck. A Manhattan jury found for the company ($MRK) in a case filed by Florida patient Linda Secrest, who claimed she suffered
Merck ($MRK) has won a significant victory in the fourth Fosamax case to hit court. U.S. District Judge John Keenan tossed all but one claim against the company, leaving it to fight patient Linda
Marketing osteoporosis drugs has grown more complicated since Merck's Fosamax went off patent a couple years ago. Now that there are low-cost alternatives to branded bisphosphonate treatments,
The judge overseeing litigation over Merck's bone drug Fosamax needs more tea leaves to read. Judge John Keenan originally thought a half-dozen bellwether cases would be enough to outline the